Status:
COMPLETED
Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline
Lead Sponsor:
Nara Medical University
Conditions:
Brain Infarction
Hypertension
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to elucidate whether or not angiotensin II receptor blockers (ARB) are more beneficial or equal to angiotensin converting enzyme inhibitors (ACEI) on development or progre...
Detailed Description
Hypertension plays a major role in the development of cardiovascular diseases. Treating hypertension has been associated with reduction in the risk of stroke and myocardial infarction. Angiotensin con...
Eligibility Criteria
Inclusion
- Patients with essential hypertension (systolic blood pressure\>=140 mmHg and/or diastolic blood pressure\>=90, or treated with antihypertensive drugs)
- Patients with any finding of stroke, silent brain infarction, and white matter lesion on magnetic resonance imaging
Exclusion
- Secondary hypertension
- Atrial fibrillation
- History or signs of cerebral disorders other than cerebrovascular disease
- Malignant tumor
- Chronic renal failure
- Severe congestive heart failure
- Hyperkalemia
- Stenosis of bilateral renal artery
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
395 Patients enrolled
Trial Details
Trial ID
NCT00126516
Start Date
May 1 2004
End Date
June 1 2013
Last Update
October 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Department of Internal Medicine, Nara Medical University
Kashihara, Nara, Japan, 634-8522